Thats exactly what I was thinking. If you look at the performance rights and shares you will find that management is strongly incentivised to perform.
CEO performance rights: Triggers at 5M, 6.5M, 8M revenue, or 500k, 750k and 1M patients, or 2500, 3750, 5000 GPs.
Founder & CR lead manager performance shares: 2500 pharmacies or 5M revenue.
MMG: 1, 2, 3, 4 & 7< revenue from HMRs.
None of those milestones are easy to achieve, in fact all of those milestones are significantly above what MDR is at right now. For instance our revenue is only ~$1.4M, less than a third of that required for our CEO to get his first 5M performance shares at $5M revenue. Our pharmacy count is around 1500, and our patient numbers is less than 200k. This is not a management that sets extremely low milestones for performance shares, and dumps them on market upon triggering those low targets, leaving shareholders holding the bag.
Monetizing the platform, page-21
-
- There are more pages in this discussion • 32 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MDR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
30.0¢ |
Change
0.010(3.45%) |
Mkt cap ! $215.0M | |||
| Open | High | Low | Value | Volume |
| 29.0¢ | 30.0¢ | 27.5¢ | $254.8K | 889.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 39326 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.5¢ | 2917 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| MDR (ASX) Chart |
